The presence of toxic cyanobacteria (blue-green algae) in surface waters used for drinking water sources and recreation is receiving increasing attention worldwide as a potential health concern (1) (2) (3) (4) (5) . Human illness resulting from exposure to blue-green algal toxins, though less common than poisonings of wild and domestic animals , has been reported (1, 2, (10) (11) (12) . In 1996, 55 hemodialysis patients died in Brazil when the dialysis water became contaminated with toxins from the blue-green alga Microcystis aeruginosa (13) .
Although potential health risks from exposure to algal toxins in surface waters have been widely recognized, potential risks from exposure through another important route-ingestion of contaminated dietary supplements made from blue-green algae (BGA)-have received only limited attention (2, 3, 6, 14) . Because of its concentrated form, the exposure potential to algal toxins in contaminated BGA products can greatly exceed potential exposure through water consumption or recreational contact.
Since 1983, the blue-green alga Aphanizomenon Jlos-aquae has been harvested from Upper Klamath Lake (UKL) in southern Oregon and marketed as a dietary supplement. These supplements are commonly consumed in the United States, Canada, and Europe for their putative beneficial effects, including "detoxification," increased energy, elevated mood, and weight loss. They are also marketed for use in children and are used as a treatment for Attention Deficit Hyperactivity Disorder (15) .
In September 1996, the Oregon Health Division (OHD) in Portland, Oregon, learned that UKL was experiencing an extensive bloom of M aeruginosa, a blue-green alga that produces potent hepatotoxins called microcystins. An investigation revealed that the M aeruginosa bloom had resulted in significant microcystin levels in the lake, and an advisory was issued recommending against water contact. The advisory prompted calls from consumers of UKL BGA products, who expressed concern about the possible contamination of these products with microcystin toxins. In response to these concerns, the OHD and the IN) . We prepared polyclonal antibodies against MCYST-LR used in an ELISA as previously described (16) . MCYST-HRP conjugate was prepared according to the method of Chu et al. (16) . The antibodies used in the assay were most specific for MCYST-LR (100%) and arginine-arginine variant (MCYST-RR; 126%), with some cross-reactivity with tyrosine-arginine variant (MCYST-YR; 65%) and nodularin (48%) (16 16 ,000 x g) to remove the cell debris or solid materials, we diluted the supernatant 10 and 100 times with distilled water and then subjected it to the cd-ELISA using the protocol previously described by Chu et al. (17) . At least two analyses were performed for each sample, and triplicates were run for each analysis. The intrawell coefficient of variation of the same sample extract in the triplicates was generally < 10%. The analytical recovery of MCYST-LR added to the blank algae extract sample (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) pg/g) in the ELISA was > 70% (17) .
Because of the known heterogeneous distribution of M aeruginosa and microcystin toxin in lake environments (18) (20) with the application of standard uncertainty factors (UFs) (19 Table 2) . Variation of the paired analyses ranged from 13 to 63%. The largest variation (0.3 and 0.78 pg/g) was found in batch sample 4, which had levels close to the present ELISA detection limit. In the other paired samples the variation was < 30%; however, a third sample from one batch (batch 5) showed a markedly lower microcystin concentration than the two other samples (< 0.04 pg/g as compared to 3.02 and 4.41 l'g/g), again indicating that microcystin heterogeneity can occur in BGA products.
Two algal samples were subjected to HPLC-ELISA. Results of a representative activity profile of the 0.5 mL fractions are shown in Figure 2 . Figure 2B shows a major inverse peak with a retention time of 25 min and a minor inverse peak with a retention time of 21 .4 min when 10 ,uL BGA extract (15 mg BGA) was injected and anti-MCYST-LR antibodies were used in the ELISA. The injection of standard MCYST-LR and MCYST-RR separately into the column resulted in single inverse peaks with retention times of 25 and 22 min, respectively (data not shown), which is consistent with our earlier studies (23) . Thus, in terms of activity, we identified the large inverse peak in the ELISA-HPLC chromatogram as MCYST-LR and the minor inverse peak as MCYST-RR. Using the ELISA standard curve, we estimated the MCYST-LR concentration in each fraction; the results are shown in Figure 2A (positive peak). The Because of the known hepatotoxic potency of microcystins, the presence of these toxins in food products is cause for concern. The toxicity of microcystins has been extensively studied (27) (28) (29) (30) (31) . After ingestion, microcystins are actively taken into the portal circulation from the digestive tract and rapidly cleared from the plasma via active transport into hepatocytes (32) (33) (34) (35) . Once inside hepatocytes, microcystins tightly bind and inhibit protein phosphatase 1 and 2A (PP1 and PP2A), resulting in the hyperphosphorylation of cellular proteins with critical roles in the maintenance of cell structure and function (31) (32) (33) (34) 36) . Acute exposure to high microcystin doses results in severe damage to the hepatocyte cytoskeleton, causing morphologic changes in hepatocytes and sinusoids and, ultimately, intrahepatic hemorrhage and hypovolemic shock (7, 14, 28) .
Although less is known about the possible health effects from exposure to lower doses of microcystins, there is increasing concern that chronic exposure to low levels may also pose a significant health risk. Potential tumor promotion is a primary concern (14,29,37-3_l) . Microcystins are believed to promote tumor formation through the inhibition of PP1 and PP2A, which are integrally Environmental Health Perspectives * VOLUME 1081 NUMBER 51 May 2000involved in cell-cycle regulation (14, 29, 39) . This mechanism of tumor promotion has been well characterized in the diarrhetic shellfish poison toxin okadaic acid (39, 40) . Evi- dence for tumor promotion by microcystins has been provided in animal (30, 38, 39) and epidemiologic (14, 39, (41) (42) (43) studies. Recent work suggests that the high incidence of primary liver cancer in China may be due, in part, to chronic exposure to microcystins in drinking water (39, (41) (42) (43) .
Continuous low-level exposure to microcystins may also result in hepatic accumulation. Studies have shown that, once taken up by the liver, microcystin excretion occurs very slowly (31, 34, 35) . Bioaccu-mulation of microcystins has been demonstrated in laboratory animals (31) and in aquatic vertebrates and invertebrates (44) . These results raise concerns that long-term exposure to even very low levels of microcystins may be significant, and could ultimately result in liver cancer and other liver diseases.
Although it is widely recognized that exposure to microcystins in drinking water represents a significant health risk, the potential for microcystin exposure may be substantially greater for consumers of BGA products. Because M aeruginosa blooms are seasonal events, microcystin concentrations in surface waters tend to be sporadic, thus allowing for regular clearing of microcystins from the liver and recovery from possible injury. However, BGA for use in dietary supplements is harvested during the bloom season and is then processed and distributed all year. Thus, if the BGA is contaminated with microcystins, the toxin exposure is continuous throughout the year. In addition, the intake of toxins from drinking water is naturally limited by water consumption rates (average 1.5-2 L/day), whereas there is virtually no limit to how much BGA can be consumed. Users of these products have reported consumption rates of as much as 20 g/day. Thus, potential exposure to microcystin toxins in BGA products is much greater than exposure through drinking water.
Concerns (2, 3, 5) , and GI disturbance is apparently a fairly common experience of BGA consumers. MedWatch has received several reports of nausea, vomiting, and diarrhea associated with BGA consumption (51) . Although GI disturbance is acknowledged by the BGA industry as a potential consequence of BGA consumption, it is attributed to "detoxification" of the body.
Many consumers of dietary supplements and other alternative health care products assume that these products could not be sold without the absolute assurance of safety. Unfortunately, because of the regulatory limits on the FDA that are imposed by the DSHEA, this is not the case. As our work with UKL BGA demonstrates, the dietary supplement industry is largely self-regulated, and assuming that these products are entirely safe may not, in fact, be a safe assumption.
